Results 171 to 180 of about 3,931 (193)
Some of the next articles are maybe not open access.
Extracorporeal photopheresis in heart transplant rejection
Transfusion and Apheresis Science, 2015Up to 25% of heart transplant recipients develop rejection requiring intervention. While the majority respond to augmentation of immunomodulatory drug therapy, a subset of patients will remain refractory. Extracorporeal photopheresis (ECP) appears particularly useful in the management of select heart transplant recipients at risk of rejection, with ...
Jignesh, Patel +3 more
openaire +2 more sources
2012
Extracorporeal photopheresis (ECP) is the first FDA approved cellular photoimmunotherapy for cancer and has demonstrated efficacy in T-cell mediated disorders including prevention and treatment of acute and chronic graft-versus-host disease, organ transplant rejection, scleroderma, Crohn s disease and diabetes mellitus.
openaire +1 more source
Extracorporeal photopheresis (ECP) is the first FDA approved cellular photoimmunotherapy for cancer and has demonstrated efficacy in T-cell mediated disorders including prevention and treatment of acute and chronic graft-versus-host disease, organ transplant rejection, scleroderma, Crohn s disease and diabetes mellitus.
openaire +1 more source
Extracorporeal photopheresis in graft‐versus‐host disease
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2008SummaryGraft‐versus‐host disease (GvHD) is a common and often serious complication of hematopoietic stem cell transplantation. There are two major forms of GvHD: an acute form which develops in the first 100days after HSCT, and a chronic form which develops later.
CARCAGNÌ M. R. +4 more
openaire +3 more sources
Nephrogenic Fibrosing Dermopathy Treated with Extracorporeal Photopheresis
Dermatology, 2004Nephrogenic fibrosing dermopathy (NFD) is a rare fibrosing skin disease of unknown etiology occurring in patients with terminal renal disease. It was first described in the year 2000. The histology of NFD shows an increased number of dendritic cells, fibroblasts and thickened collagen fibers resembling scleromyxedema.
Lauchli, S +4 more
openaire +3 more sources
Extracorporeal photopheresis: How, when, and why
Journal of Clinical Apheresis, 2011AbstractExtracorporeal photopheresis (ECP) is a well‐tolerated procedure that suppresses T‐lymphocyte activity in a clonally‐specific way. It is an effective therapy that has established indications in the management of cutaneous T‐cell lymphoma, graft‐versus‐host disease and some scenarios of solid‐organ transplant rejection.
openaire +2 more sources
International Journal of Dermatology, 1994
M, Gross, E E, Boh, L E, Millikan
openaire +2 more sources
M, Gross, E E, Boh, L E, Millikan
openaire +2 more sources
[Update on extracorporeal photopheresis].
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2016Extracorporeal photopheresis (ECP) is a treatment approach that combines leukapheresis with photochemotherapy and is derived from PUVA; with this procedure, nucleated cells such as lymphocytes and monocytes are extracorporeally irradiated with UVA light after photosensitization.
U, Just, R, Knobler
openaire +1 more source
Extracorporeal Photochemotherapy (Photopheresis)
2021Sa Rang Kim, Michael Girardi
openaire +1 more source